Migraine Headaches

CHICAGO — A novel nasal spray formulation of bumetanide, a commonly used diuretic for patients with HF, had similar safety, tolerability, relative bioavailability and pharmacodynamics to the oral and IV versions, researchers reported.

Poor sleep quality and low energy on the previous day were associated with incident morning headache, while higher than average energy levels and stress were linked to later-day headache onset, researchers reported in Neurology.

With an estimated 1 billion people affected by migraine worldwide, there is an urgent need to provide effective treatment for this debilitating disease.

Lusaris Therapeutics announced its launch with $60 million in Series A financing to advance LSR-1019, a sublingual formulation of 5-MeO-DMT for patients with treatment-resistant depression and other severe neuropsychiatric disorders.

LAS VEGAS — To address patient need, affordability and physician-assisted treatment plans, a range of prevention therapies should be offered to those with migraines, according to a presenter at BRAINWeek 2022.

One of several plenary sessions at the American Headache Society Annual Meeting, which is being held virtually, focused on sex- and gender-specific differences in headache.